VLX

(2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide

Created:2023-07-28
Last modified:  2024-05-01

Find related ligands:

Chemical Details

Formal Charge0
Atom Count35
Chiral Atom Count2
Bond Count35
Aromatic Bond Count0
2D diagram of VLX

Chemical Component Summary

Name(2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide
Systematic Name (OpenEye OEToolkits)(2~{S})-2-[(4~{R})-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide
FormulaC11 H20 N2 O2
Molecular Weight212.289
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385CCC[CH]1CN([CH](CC)C(N)=O)C(=O)C1
SMILESOpenEye OEToolkits2.0.7CCCC1CC(=O)N(C1)C(CC)C(=O)N
Canonical SMILESCACTVS3.385 CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Canonical SMILESOpenEye OEToolkits2.0.7 CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
InChIInChI1.06 InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
InChIKeyInChI1.06 MSYKRHVOOPPJKU-BDAKNGLRSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB05541 
NameBrivaracetam
Groups
  • approved
  • investigational
DescriptionBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].
SynonymsBrivaracetam
Brand Names
  • Auro-brivaracetam
  • Apo-brivaracetam
  • Briviact
  • Brivlera
IndicationUsed as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
Categories
  • Anticonvulsants
  • Central Nervous System Agents
  • Central Nervous System Depressants
  • Cytochrome P-450 CYP2B6 Substrates
  • Cytochrome P-450 CYP2C19 Substrates
ATC-CodeN03AX23
CAS number357336-20-0

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Synaptic vesicle glycoprotein 2AMEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFE...unknownunknown
Sodium channel proteinMEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPK...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 2C19MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...unknownsubstrate
Cytochrome P450 2B6MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL607400
PubChem 9837243
ChEMBL CHEMBL607400
ChEBI CHEBI:133013
CCDC/CSD NASROP01, NASROP, ZIKFOR